Please assess the completion status of the following clinical trial:

Trial Title: Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>= 18 years.~2. ≥1 set of blood cultures positive for MRSA~3. Able to be randomized within 72 hours of blood cultures being collected.~4. Likely to remain as inpatient for 7 days following randomization~Exclusion Criteria:~1. Previous type 1 hypersensitivity reaction to ß-lactams~2. Polymicrobial bacteraemia (not counting contaminants)~3. Previous participation in the trial~4. Known pregnancy~5. Current β-lactam antibiotic therapy which cannot be ceased or substituted~6. Participant's primary clinician unwilling to enrol patient~7. Moribund (expected to die in next 48 hours with or without treatment)~8. Treatment limitations which preclude the use of antibiotics Note that we are NOT planning to exclude participants with renal failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard therapy (Type: NO_INTERVENTION): Intravenous vancomycin dosed as per Australian Therapeutic Guidelines (loading dose of 25 mg/kg followed by maintenance dose of 15-20 mg/kg every 12 hours) with subsequent adjustment to maintain trough levels at 15-20 mg/dL OR Intravenous daptomycin 6-10 mg/kg per day, adjusted for renal function (details of renally adjusted dosing provided in full protocol).~The choice of daptomycin or vancomycin is clinician-determined and may be influenced by such factors as local practice, the vancomycin minimum inhibitory concentration (MIC) of the isolate and evidence emerging during the course of the study
- Standard therapy + Beta-Lactam (Type: EXPERIMENTAL): In addition to standard treatment an intravenous Beta-Lactam (β-lactam) will be added for the first 7 calendar days following randomisation (randomisation is day 1 - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous flucloxacillin 2g every 6 hours in Australia and intravenous cloxacillin 2g every 6 hours in Singapore. For those with a history of minor allergy to any penicillin (rash or unclear history, but not anaphylaxis or angiooedema), it will be intravenous cefazolin 2g every 8 hours. For haemodialysis patients, it will usually be cefazolin 2g three times per week post dialysis, however clinicians are also free to choose intermittent (flu)cloxacillin, dosed as for glomerular filtration rate (GFR ) \<10, if they desire.

Based on this trial design, predict the completion outcome and termination type (if applicable).